Citi downgraded Penumbra (PEN) to Neutral from Buy with a price target of $374, up from $350, after Boston Scientific (BSX) entered an agreement to acquire Penumbra in a cash and stock transaction valued at $14.5B, or $374 per share. Citi cites the pending deal for the downgrade.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Midday Fly By: TSMC reports Q4 beat, Goldman Sachs raises dividend
- Penumbra downgraded to Equal Weight from Overweight at Wells Fargo
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Penumbra rises 11.9%
- M&A News: Penumbra Stock (PEN) Beats Harder on $14.5B Boston Scientific (BSX) Acquisition